Peptide Pattern Biomarker for Arthrosis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for arthrosis lack reliable biomarkers, making early and accurate diagnosis challenging, as existing methods rely on symptom evaluation and radiological changes without specific serum or synovial fluid markers.
Innovation Solution
Identification of a unique peptide pattern in serum samples from arthrosis patients using chemical depletion, tryptic digestion, and MALDI-TOF/TOF mass spectrometry, which differentiates arthrosis from other rheumatic diseases and healthy subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If blood tests are performed using conventional rheumatic markers, then other rheumatic diseases can be excluded, but arthrosis cannot be diagnosed or followed up
Solution Approach 1:
The patent extracts and identifies specific peptide markers (including COMP and keratan sulfate derivatives) from the complex biological fluid that are uniquely associated with arthrosis. This extraction of specific diagnostic information from the background of normal blood test results enables arthrosis diagnosis while maintaining the ability to exclude other rheumatic diseases through conventional markers.
Solution Approach 2:
The patent changes the diagnostic parameters from conventional rheumatic markers (which show normal results in arthrosis) to peptide-based markers derived from cartilage breakdown products. This parameter change allows detection of arthrosis-specific pathological processes while preserving the utility of conventional markers for differential diagnosis.
2Ease of operation
If diagnosis is based on symptom evaluation and physical examination, then clinical assessment can be performed, but early and accurate diagnosis is challenging
Solution Approach 1:
The patent introduces peptide markers as intermediary biological indicators that mediate between the pathological processes of cartilage degradation and the diagnostic assessment. These markers serve as measurable intermediaries that reflect early cartilage damage before radiological changes occur, bridging the gap between clinical symptoms and objective diagnostic evidence.
Solution Approach 2:
The patent enables preliminary detection of arthrosis through peptide marker analysis before radiological changes become apparent. This preliminary diagnostic action allows early intervention and treatment planning based on biochemical evidence of cartilage breakdown, preceding the structural changes detectable by X-ray.
3Measurement precision
If radiological studies are used to determine severity, then precise severity assessment is achieved, but early diagnosis before radiological changes is not possible
Solution Approach 1:
The patent performs preliminary diagnostic detection using peptide markers before radiological changes occur. The peptide analysis provides early warning of cartilage degradation, allowing diagnosis and treatment initiation before the time loss associated with waiting for radiological evidence.
Solution Approach 2:
The patent adds a new diagnostic dimension by moving from structural assessment (radiology) to biochemical assessment (peptide markers). This dimensional shift from anatomical to molecular level detection enables early diagnosis independent of radiological timing, providing complementary information about disease activity and severity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide pattern provides a specific and reliable marker for diagnosing arthrosis, enabling early detection and differentiation from other rheumatic conditions, potentially improving treatment outcomes and reducing healthcare costs.
Implementation Method 1
MALDI-TOF/TOF mass spectrometry
Implementation Method 2
tryptic digestion
Implementation Method 3
tryptic digestion
Implementation Method 4
chemical depletion with dithiothreitol (DTT) and acetonitrile (ACN)
Data Source
Figure 1
AI summary
The invention relates to a peptide pattern characteristic of subjects who suffer from arthrosis, and to the use of said peptide pattern in the diagnosis of said disease. Consequently, the present invention also relates to an in vitro method for diagnosis and to a kit for implementing said method.